New weekly shot shows promise for shedding pounds in obesity trial
NCT ID NCT04904913
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new medicine called IBI362, given as a weekly shot, to help overweight and obese adults lose weight. About 328 Chinese participants received either the drug or a placebo for 24 weeks, while also following diet and exercise plans. The main goal was to see how much weight they lost compared to those on placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVERWEIGHT , OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University people's hospital
Beijing, Beijing Municipality, 100044, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can patients power their own obesity research?
- Can antioxidant pills boost skin and blood carotenoids to improve cardiometabolic health?
- Could a daily probiotic help you feel fuller and eat less?
- Heart safety check for new Weight-Loss drug candidate
- Fasting plus fibre: a Gut-Boosting combo?
- AI health coach gives Real-Time weight loss tips via smartphone